1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Drugs In Development, 2022, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 4 and 3 respectively.
Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Progressive Multifocal Leukoencephalopathy - Overview
- Progressive Multifocal Leukoencephalopathy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development
- Biological E Ltd
- Cellevolve Bio
- Evrys Bio
- Excision BioTherapeutics Inc
- Genexine Inc
- Inhibikase Therapeutics Inc
- Neurimmune Holding AG
- Pomona Ricerca SRL
- Vir Biotechnology Inc
- Progressive Multifocal Leukoencephalopathy - Drug Profiles
- CEVST-01JC - Drug Profile
- Product Description
- Mechanism Of Action
- EBT-103 - Drug Profile
- Product Description
- Mechanism Of Action
- efineptakin alfa - Drug Profile
- Product Description
- Mechanism Of Action
- IkT-01427 - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody for John Cunningham Infections and Progressive Multifocal Leukoencephalopathy - Drug Profile
- Product Description
- Mechanism Of Action
- NI-307 - Drug Profile
- Product Description
- Mechanism Of Action
- PNJC-1 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Vaccine for Progressive Multifocal Leukoencephalopathy - Drug Profile
- Product Description
- Mechanism Of Action
- Progressive Multifocal Leukoencephalopathy - Dormant Projects
- Progressive Multifocal Leukoencephalopathy - Product Development Milestones
- Featured News & Press Releases
- Sep 20, 2022: Cellevolve Bio submits Investigational New Drug (IND) application for global phase 2, placebo-controlled study of CE-VST01-JC for the treatment of Progressive Multifocal Leukoencephalopathy (PML)
- Dec 01, 2021: Cellevolve announces global partnership with QIMR Berghofer Medical Research Institute to advance novel off-the shelf T-cell therapy in the first randomized cell therapy trial for progressive multifocal leukoencephalopathy (PML)
- May 24, 2021: NeoImmuneTech announces first patient dosed in the pilot study of NT-I7 (efineptakin alfa) in progressive multifocal leukoencephalopathy
- Feb 23, 2021: NeoImmuneTech receives U.S. FDA IND clearance for pilot study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
- Jun 15, 2020: NeoImmuneTech receives FDA orphan drug designation for NT-I7 (efineptakin alfa) for the treatment of progressive multifocal leukoencephalopathy
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Progressive Multifocal Leukoencephalopathy, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Progressive Multifocal Leukoencephalopathy - Pipeline by Biological E Ltd, 2022
- Progressive Multifocal Leukoencephalopathy - Pipeline by Cellevolve Bio, 2022
- Progressive Multifocal Leukoencephalopathy - Pipeline by Evrys Bio, 2022
- Progressive Multifocal Leukoencephalopathy - Pipeline by Excision BioTherapeutics Inc, 2022
- Progressive Multifocal Leukoencephalopathy - Pipeline by Genexine Inc, 2022
- Progressive Multifocal Leukoencephalopathy - Pipeline by Inhibikase Therapeutics Inc, 2022
- Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, 2022
- Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, 2022
- Progressive Multifocal Leukoencephalopathy - Pipeline by Vir Biotechnology Inc, 2022
- Progressive Multifocal Leukoencephalopathy - Dormant Projects, 2022
- Number of Products under Development for Progressive Multifocal Leukoencephalopathy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biological E Ltd
- Cellevolve Bio
- Evrys Bio
- Excision BioTherapeutics Inc
- Genexine Inc
- Inhibikase Therapeutics Inc
- Neurimmune Holding AG
- Pomona Ricerca SRL
- Vir Biotechnology Inc
